Protalix BioTherapeutics, Inc.
PLX
$1.67
$0.000.00%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.01% | 54.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.01% | 54.83% | |||
| Cost of Revenue | 41.81% | -28.24% | |||
| Gross Profit | -2.67% | 406.36% | |||
| SG&A Expenses | 11.62% | 0.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.52% | 1.60% | |||
| Operating Income | 81.83% | 128.28% | |||
| Income Before Tax | 238.73% | 117.71% | |||
| Income Tax Expenses | -123.34% | 539.82% | |||
| Earnings from Continuing Operations | 1,335.98% | 104.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,335.98% | 104.53% | |||
| EBIT | 81.83% | 128.28% | |||
| EBITDA | 63.38% | 140.33% | |||
| EPS Basic | 1,314.29% | 104.45% | |||
| Normalized Basic EPS | 233.96% | 117.43% | |||
| EPS Diluted | 1,385.00% | 104.24% | |||
| Normalized Diluted EPS | 239.22% | 116.78% | |||
| Average Basic Shares Outstanding | 0.79% | 2.68% | |||
| Average Diluted Shares Outstanding | -0.56% | 6.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||